Clinical Trial Update: A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001 [Phase 1, Phase 2]

View source ↗

Summary

A two-arm, repeat-dose, open-label Phase 1/2 trial evaluating two intravitreal doses of VP-001 in participants with PRPF31 mutation-associated retinal dystrophy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinal Degeneration
• Retinitis Pigmentosa

Drugs mentioned

• VP-001

Snippet

Sponsor: PYC Therapeutics | Conditions: Retinitis Pigmentosa 11, Retinal Degeneration | Phase 1, Phase 2 | Status: RECRUITING